Financial Performance - Q3 2025 revenue reached $482 million, an 8% increase compared to Q3 2024[17] - Adjusted Gross Profit for Q3 2025 was $156 million, a 13% increase compared to Q3 2024[17] - Adjusted EBITDA for Q3 2025 was $96 million, a 20% increase compared to Q3 2024[17] Segment Performance - Equipment Rental Solutions (ERS) revenue increased by 12%, or $18 million, in Q3 2025 compared to Q3 2024[48] Rental revenue increased by 18%, or $19 million[48] - Truck & Equipment Sales (TES) revenue increased by 6%, or $16 million, in Q3 2025 compared to Q3 2024[57] - Aftermarket Parts & Service (APS) revenue increased by 3% in Q3 2025 compared to Q3 2024[59] Fleet and Utilization - The company's specialty rental fleet consists of more than 10,350 vehicles with an original equipment cost (OEC) of $1.62 billion[18] - Average utilization for ERS in Q3 2025 was over 79%, the highest quarterly average in over two years[53] - Average OEC on Rent increased by $180 million and average utilization increased by 610 basis points in Q3 2025 compared to Q3 2024[53] Market Dynamics - The company operates in favorable end markets with positive secular tailwinds, including T&D, Rail, Telecom, and Infrastructure[14] - U S IOU T&D Capex annual total spend in 2024 was ~$91 billion with 8.7% '20-'24 CAGR[21] - U S Telecom / Broadband Capex LTM Spend @ 06/30/25 was $13B+ with 7.9% '21-LTM CAGR[21] Financial Position - Total available liquidity is over $480 million[63] - The company reaffirms its 2025 outlook, projecting consolidated revenue between $1.97 billion and $2.06 billion, representing a 9% to 14% growth[64] Adjusted EBITDA is projected between $370 million and $390 million, representing a 9% to 15% growth[64]

Financial Performance - NextEra Energy's adjusted earnings per share increased by 9.7% year-over-year[6] - Adjusted earnings increased from $2.127 billion in 2024 to $2.348 billion in 2025[7] - Adjusted EPS increased from $1.03 in 2024 to $1.13 in 2025[7] Florida Power & Light (FPL) - FPL's earnings per share increased by $0.08 from the prior-year comparable quarter[18] - FPL's EPS increased from $0.63 in 2024 to $0.71 in 2025[19] - FPL's regulatory capital employed grew by approximately 7.8% from Q3 2024 to Q3 2025, reaching $74.2 billion[22] NextEra Energy Resources (NEER) - NextEra Energy Resources' adjusted earnings per share increased by $0.06 from the prior-year comparable quarter[29] - NextEra Energy Resources' adjusted EPS increased from $0.47 in 2024 to $0.53 in 2025[33] - NextEra Energy Resources added 3.0 GW of new renewable and storage projects to its backlog since the second quarter call[34] - Renewables and storage backlog stands at approximately 29.6 GW[36] Future Outlook - NextEra Energy expects a 6% to 8% annual adjusted EPS growth rate through 2027, off the 2024 adjusted EPS expectations range[44] - NextEra Energy expects approximately 10% annual dividend per share growth through at least 2026[44]

Ramaco Overview - Ramaco shipped metallurgical coal to steelmakers in over 20 countries[9] - Ramaco's 2024 sales volume was 40 million tons, with an adjusted EBITDA of $106 million[12] - As of October 27, 2025, Ramaco's market capitalization was $20 billion, with revenue of $666 million in 2024 and net cash of $77 million as of September 30, 2025[12] Brook Mine Expansion and Economics - The Brook Mine is projected to have a steady-state annual production of approximately 3,414 short tons of rare earths and critical minerals[13,56] - The revised total Capex requirement for Brook Mine is $1125 million, with an NPV (8%) of $51 billion and a 3-year payback period[21] - Brook Mine is projected to generate over $500 million in EBITDA by 2028, a 276% increase compared to the Fluor PEA[21] - At steady state, the Brook Mine is expected to generate $1038 million in revenue and $552 million in EBITDA, representing a 53% margin[56] Rare Earths and Critical Minerals Opportunity - Brook Mine is believed to be the only primary mine source of Gallium, Germanium, and Scandium in the world[10,14,39] - Approximately 40% of the total estimated REO production consists of primary magnetic REOs, gallium, germanium, and scandium, accounting for ~99% of annual revenue from the Brook Mine[40] - China holds dominant market shares in Gallium (>95%), Heavy Rare Earths (>90%), Light Rare Earths (85%), Scandium (>60%), and Germanium (65%)[25] Metallurgical Coal Business - Ramaco's cash costs of $100 per ton for YTD 2025 are among the lowest of its publicly traded peer group[16] - Ramaco's 2025 production guidance is between 37 million and 39 million tons[88]

Financial Performance - The company's net income for 3Q25 was $106.0 million, resulting in diluted earnings per share of $1.54[22] - The company's return on average assets (ROA) was 1.56% for 3Q25[22] - The company's return on average tangible common equity (ROTCE) was 14.57% for 3Q25[22] - The company's net interest margin (NIM) improved by 3 basis points to 3.80% in 3Q25[22] - The company's efficiency ratio improved to 49.19% in 3Q25[22] Balance Sheet and Capital - The company's tangible book value (TBV) grew by $1.58 per share to $42.90 at the end of 3Q25, representing an annualized growth rate of 15.2%[22] - The company's CET1 ratio was 13.2% at the end of 3Q25[13] - Noninterest-bearing deposits remained strong, representing 30.4% of total deposits as of September 30, 2025[22] Loan Portfolio and Credit Quality - The company's loan portfolio totaled $21.3 billion in 3Q25[56] - The company's allowance for credit losses (ACL) on loans was 1.62% of total loans in 3Q25[13] - The company's net charge-offs were stable at 0.14% annualized in 3Q25[22] Market Position and Growth - The company's Southeast markets are projected to grow approximately 1.7x the national average over the next five years[13]

Financial Performance - Novartis Q3 2025 net sales reached USD 13909 million, a 7% increase in constant currencies compared to Q3 2024[19, 108] - Core operating income also grew by 7% in constant currencies, reaching USD 5460 million in Q3 2025[19, 108] - The core margin was 393% in Q3 2025[19, 108] - Free cash flow for 9M 2025 was USD 15941 million, a 26% increase compared to 9M 2024[108, 112] - The company reaffirms its 2025 full-year guidance, expecting high single-digit sales growth and low-teens core operating income growth in constant currencies[20, 119, 120] Key Products Growth - Kisqali experienced a 68% growth in constant currencies during Q3[25, 27] - Kesimpta sales increased by 44% in constant currencies in Q3[25, 40, 41] - Pluvicto sales grew by 45% in constant currencies in Q3[25, 47, 48] - Scemblix sales increased by 95% in constant currencies in Q3[25, 67, 68] - Leqvio sales grew +54% cc in Q3[60, 61] Pipeline and Innovation - Rhapsido received FDA approval for Chronic Spontaneous Urticaria (CSU)[22, 88] - Ianalumab showed positive Phase III results in Sjögren's Disease (SjD)[22, 93] - Pluvicto's PSMAddition trial demonstrated a 28% reduction in risk of progression or death in PSMA+ mHSPC patients[54, 59]

Financial Performance - Xylem's Q3 2025 reported revenue reached $2268 million, reflecting an 8% overall growth[6] - The organic growth for Q3 2025 was 7%[6] - Adjusted EBITDA margin for Q3 2025 hit a record 232%, a 200 bps year-over-year expansion[7, 11] - Adjusted EPS for Q3 2025 increased by 23%[7, 11] - The company is raising its full-year guidance to reflect robust year-to-date results and a positive outlook[8] Segment Performance - Water Infrastructure reported revenue of $656 million with 5% overall growth and 5% organic growth[6] - Applied Water reported revenue of $456 million with 2% overall growth and 1% organic growth[6] - Measurement and Control Solutions reported revenue of $522 million with 14% overall growth and 11% organic growth[6] - Water Solutions and Services reported revenue of $634 million with 10% overall growth and 10% organic growth[6] Guidance and Assumptions - The updated full-year revenue guidance is approximately $9 billion, representing a 5-6% total growth and 4-5% organic growth[19] - The adjusted EBITDA margin guidance for the full year is 220-223%, a 140-170 bps expansion[19] - The adjusted EPS guidance for the full year is $503-$508[19]

Lacutamab KOL Event Clinical perspectives and Commercial outlook New-York, October 28th, 2025 Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expr ...

Financial Performance - Smithfield achieved a record third quarter adjusted operating profit of $310 million, an increase of 8.5% year-over-year, with an 8.3% adjusted operating profit margin[22] - The company's sales increased by 12.4% to $3,747 million in the third quarter of 2025, compared to $3,334 million in the same period of 2024[101] - Adjusted net income increased by 13.7% to $230 million, compared to $203 million in the prior year[101] - Adjusted EPS increased by 9.4% to $0.58, compared to $0.53 in the prior year[101] Segment Performance - Packaged Meats segment delivered its second-highest third-quarter adjusted operating profit despite a challenging market[22] - Packaged Meats sales increased by 9.1%, driven by a 9.2% increase in price, with volume remaining relatively flat[109] - Fresh Pork sales increased by 12.0% due to a 12.0% increase in price, while volume remained relatively flat[117] - Hog Production saw a 119.8% increase in adjusted operating profit[124] Strategic Initiatives - The company is focused on increasing profits in the Packaged Meats segment through enhanced product mix and volume growth[27] - Smithfield aims to achieve a best-in-class cost structure in its Hog Production segment through genetic transformation, herd health improvements, and procurement and nutrition savings[27] - The company is optimizing operations by delivering efficiencies across manufacturing, supply chain, distribution, procurement, and SG&A[27] - Smithfield anticipates paying annual dividends of $1.00 per share[5, 23]

Financial Performance - Q3 2025 - Chlor Alkali Products & Vinyls segment sales were $924 million, with adjusted EBITDA of $237 million[11, 12] - Epoxy segment sales were $350 million, with an adjusted EBITDA loss of $19 million[18] - Winchester segment sales were $440 million, with adjusted EBITDA of $33 million[24] - Olin Corporation's Q3 2025 Adjusted EBITDA was $222.4 million, compared to $176.1 million in Q2 2025 and $160.3 million in Q3 2024[60, 62] Key Highlights & Actions - Olin recognized a $32 million net benefit from Section 45V Clean Hydrogen Production tax credits in the Chlor Alkali Products & Vinyls segment[16] - Winchester is shifting production toward international military sales and lowering commercial production to reduce inventory levels[29] - The company expects to lower current debt levels, targeting year-end 2025 net debt comparable to year-end 2024[36] Outlook - Q4 2025 - Olin anticipates Q4 2025 adjusted EBITDA to be between $110 million and $130 million, including a ~$40 million penalty from planned inventory reductions[38] - The company expects caustic soda price improvement and aims to preserve ECU values despite seasonally weak demand in the CAPV segment[38] - Olin plans aggressive inventory reductions and will execute the Freeport turnaround safely and on budget[38]

Financial Performance - The company reported a comprehensive loss of $(0.77) per share [6] - The economic return on book value was (6.3)% [6] - Excluding litigation settlement expense, the economic return on book value was 7.6% [6] - A common stock dividend of $0.34 per share was declared [6, 13] Portfolio Composition - The investment portfolio totaled $13.5 billion [6] - The portfolio composition included Agency RMBS of $6.5 billion, MSR of $2.6 billion, and cash & cash equivalents of $0.8 billion [18] - The company's economic debt-to-equity ratio was 7.2x [6] MSR Portfolio - The fair value of the MSR portfolio was $2.627 billion [41] - The UPB (Unpaid Principal Balance) of the MSR portfolio was $177.216 billion [41] - The weighted average 3-month CPR (Conditional Prepayment Rate) for the MSR portfolio was 6.0% [41]